DioGenix, Inc., a Gaithersburg, MD-based molecular diagnostics company, raised $1.5m in Series B financing.
Backers include existing investors Nerveda LLC, a private life science fund dedicated to advancing novel therapeutic and diagnostic technologies for neurodegenerative diseases.
Led by Larry Tiffany, President and CEO, and Cam Gallagher, Chairman of DioGenix and President of Nerveda LLC, the company DioGenix develops novel molecular tests using application-specific, high-resolution state-of-the-art technologies that measure well-established human biology. The company’s lead product, MSPrecise™, is currently being evaluated in a trial to evaluate its clinical performance in identifying patients that have, or are at risk of developing multiple sclerosis.
The company intends to use the capital for a multi-site clinical trial to validate MSPrecise™.